MNG641
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.386
- PROTEIN_SECRETION+0.375
- G2M_CHECKPOINT+0.351
- MYC_TARGETS_V1+0.311
- ANDROGEN_RESPONSE+0.210
- UV_RESPONSE_DN+0.209
- SPERMATOGENESIS+0.197
- INTERFERON_ALPHA_RESPONSE+0.186
- NOTCH_SIGNALING+0.159
- PANCREAS_BETA_CELLS+0.111
Top 10 suppressed
- HYPOXIA-0.368
- TNFA_SIGNALING_VIA_NFKB-0.352
- MYOGENESIS-0.330
- MYC_TARGETS_V2-0.312
- P53_PATHWAY-0.294
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.267
- CHOLESTEROL_HOMEOSTASIS-0.235
- ESTROGEN_RESPONSE_EARLY-0.228
- IL6_JAK_STAT3_SIGNALING-0.192
- GLYCOLYSIS-0.188
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | R144 | — | — | 0.842 |
| 2 | SJEPD030795_D2.RNA-Seq | EPN | Posterior Fossa EPN | 0.797 |
| 3 | R411 | — | — | 0.793 |
| 4 | SRR3147748 | — | — | 0.790 |
| 5 | BS_X4X1SFSE | high-grade glioma | — | 0.790 |
| 6 | R137 | — | — | 0.785 |
| 7 | SRR650203 | — | — | 0.774 |
| 8 | SRR3147744 | — | — | 0.764 |
| 9 | MNG727 | — | — | 0.754 |
| 10 | MBCProject_0096_T1_RNA | — | C | 0.748 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.386 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.375 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.351 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.311 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.210 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.209 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.197 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.186 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.159 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.111 | Cobimetinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.106 | Remibrutinib | — uncovered |
| PEROXISOME | 0.098 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.077 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.070 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.060 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.055 | Inavolisib | — uncovered |
| COMPLEMENT | 0.021 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.016 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.004 | Inavolisib | — uncovered |